Q2 2023 Charles River Laboratories International Inc Earnings Call
Please standby your program is about to begin.
If you need assistance during your conference today, Please press Star zero.
Ladies and gentlemen, thank you for standing by.
Welcome to the Charles River Laboratories second quarter 2023 earnings Conference call.
This call is being recorded at.
At this time all participants are in a listen only mode.
After the speaker's presentation, there will be a question and answer session.
To ask a question. During this period, you will need to press star one on your telephone.
If you want to remove yourself from the queue. Please press star two.
Lastly, if you should require operator assistance. Please press star Zero I would now like to turn the conference over to our host Todd Spencer Vice President of Investor Relations. Please go ahead.
Good morning, and welcome to Charles River Laboratories second quarter 2023 earnings Conference call and webcast. This morning, I'm joined by Jim Foster Chairman, President and Chief Executive Officer, and Fabio Pease Executive Vice President and Chief Financial Officer, They will comment on our results for the second quarter of 2023.
Following the presentation. They will respond to questions. There is a slide presentation associated with today's remarks, which is posted on the Investor Relations section of our website at IR Dot C River dotcom.
Webcast replay of this call will be available beginning approximately two hours after the call today and can also be accessed on our Investor Relations website. The replay will be available through the next quarters conference call.
I'd like to remind you of our safe Harbor, all remarks that we make about future expectations plans and prospects for the company constitute forward looking statements under the private Securities Litigation Reform Act of 1995 actual results may mature differ materially than those indicated.
During this call we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results from results of operations prepared in accordance with GAAP in accordance with <unk>.
Regulation G. You can find the comparable GAAP measures and reconciliations on the Investor Relations section of our website I will now turn the call over to Jim Foster.
Good morning.
We were pleased with our second quarter financial performance, including organic revenue growth of 11, 2%.
As expected revenue growth rates in the RMS and manufacturing segments improved from first quarter levels in the DSA segment had another strong quarter with low double digit revenue growth and operating margin improvement.
<unk> performance reflected the substantial scale and duration of our backlog, which has enabled us to effectively manage the business.
Yeah, we are narrowing our revenue growth in our non-GAAP earnings per share guidance to the upper end of the previous ranges.
This update largely reflects the successful implementation of our mitigation efforts surround an HP supply for which I will provide additional detail. Shortly however, we continue to expect the second half growth rates to be pressured primarily in the DSA segment as a result of three <unk>.
Mary factors first the current market conditions are resulting in a continuation of the <unk>.
Lower backlog and booking trends second.
DSA segment faces a challenging year over year comparison.
After having generated organic revenue growth of 23, 6% in the second half of 2022, and finally, we still expect a modest impact just from an HP supply constraints principally in the third quarter.
We are also closely monitoring the near term demand trends of our biopharmaceutical clients as they appear to be re prioritizing their pipelines and tightening their R&D budgets.
This is affecting our industry and our company, but we will continue to leverage our significant DSA backlog and intend to appropriately manage the business and its still more cautious biopharma spending environment.
During times of funding, our macroeconomic uncertainty clients outlook for even more efficiency and speed to market and we believe they will continue to choose an industry leader like Charles River in order to derive additional value from our flexible and efficient outsourcing solutions.
With regard to an HP supply we had been effective in our efforts to leverage our global safety assessment infrastructure to alleviate the overall impact of supply constraints caused by the suspension of Cambodian imports into the U S.
Significant progress to better utilize our sites outside of the U S.
Based on our progress today, we believe that we have successfully mitigated the logistical challenges posed by the current <unk> supply constraints.
Conducting more studies.
U S and better leveraging our global infrastructure, which is a competitive advantage for Charles River.
We have been able to effectively transfer of safety assessment work between sites because much of our capacity was built flexibly to accommodate multiple species of both small and large models.
A transition of this work to our international sites. This year as required time to study scheduling logistics quarantine operations and retraining, our staff as well as working with local government agencies. However, we have already made significant progress with these initiatives and do not foresee any.
Meaningful that H P supply constraints affecting the business in the fourth quarter and next year. As a result, we now expect the impact from an HP supply constraints will be less than our initial outlook of 2% of a 2% to 4% impact to consolidated revenue growth.
This year.
We have narrowed our DSA organic revenue growth outlook to the mid single digits or the upper end of the prior range to reflect this positive update and then HP supply, but we also expect this favorable impact to be largely offset by the current DSA demand trends.
Going forward, we are operating under the assumption that we will conduct meaningfully less and HP related study work in the U S. As our international infrastructure will be sufficient to accommodate this work.
Yes.
I will now provide highlights of our second quarter performance.
We reported revenue of one point over $6 billion in the second quarter of 2023, and eight 9% increase over last year organic revenue growth of 11, 2% was driven by strong performance in the RMS and DSA segments as well as an improvement in the manufacturing growth.
Rate led by the CMO business by client segment second quarter revenue growth was broad based across global Biopharma biotech and academic and government institutions. However, demand from global biopharmaceutical clients modestly outpaced small and midsize biotech clients.
For the second consecutive quarter.
This demonstrates the diversity and stability of our overall client base as globals continue to move their critical programs forward at a time when biotechs have being more selective with.
With spending.
To extend the cash runway as the operating margin was 24% a decrease of 140 basis points year over year. The decline was driven by continued margin pressure in the manufacturing segment as well as higher unallocated corporate costs.
Earnings per share were $2 69.
A decrease of two 9% from the second quarter of last year as anticipated the year over year increase in interest expense and the tax rate continued to be meaningful headwinds to earnings growth this year as well.
The divestiture of the avian vaccine business.
As I mentioned earlier, we have narrowed our revenue and non-GAAP earnings per share guidance ranges for the year to the upper ends of the ranges due largely to the successful implementation of HP mitigation efforts.
We are narrowing our organic revenue growth guidance to a range of five 5% to seven 5%.
non-GAAP earnings per share guidance to a range of $10 30.
To $10 90 for 2023.
We have increased the lower end of the range by 50 basis points and 40 per share respectively. We believe our existing DSA backlog and our in depth assessment of the normalizing demand trends gives us continued confidence in our financial outlook for this year.
I'd like to provide you with additional details on our second quarter segment performance beginning with the DSA segment's results.
CSA revenue in the second quarter was $663 5 million an increase of 11, 7%.
On an organic basis, the safety assessment business continued to drive DSA revenue growth and contributions from base pricing and steady volume.
And HP pricing was a small benefit to the growth rate, although less of a benefit than in <unk>.
Meyer quarters, the second quarter performance of the discovery services business.
Which posted lower revenue compared to the prior year was reflective of the current market environment, coupled with the shorter term nature of both discovery projects and that business is backlog.
TSA backlog decreased modestly on a sequential basis to $2 8 billion at the end of the second quarter from $3 billion at the end of the first quarter net bookings and proposal activity continuing to trend lower with net book to Bill remaining below one times on a quarterly basis.
Primarily driven by the cancellation rate, which trended higher and accelerated in the second quarter. We believe the cancellation rate has increased because during the peak demand environment over the last few years clients booked studies further in advance of when the work would be required that.
Clients are rationalizing lower priority projects in their pipeline. They are cancelling the associated studies, we view this trend.
Lastly, a reversion to the mean.
<unk> as clients complete the pipeline rationalization process cancellation rates will decline in the backlog will be more reliable more reliably reflect the actual steady demand.
I believe the cancellations will decline because incoming new business awards.
Gross booking activity that is not adjusted for cancellations remained robust, resulting in a gross book to bill remaining above one times in the second quarter. We now see clients booking closer to end studies are required which increases the reliability of the backlog.
What level of gross bookings can support healthy revenue growth rates.
Suggests that solid underlying growth prospects for the safety assessment business will return once the rate of cancellations subsides.
We believe the stabilization of the demand trends will be supported by encouraging macroeconomic indicators.
As well as stable to improving biotech funding levels in the second quarter biotech funding showed.
The first quarter over year increases in seven quarters on a trailing 12 month basis.
We also have an average of 13 months of revenue courage safety coverage in our safety assessment backlog. This solid backlog coverage affords us the ability to appropriately manage the business through fluctuations in demand environment backfill gaps and steady schedule and meet our near term financial targets.
In addition, our level of backlog coverage for the remaining quarters in 2023 is well above the historical pre pandemic averages, which gives us additional confidence about the resilience of the business and our ability to achieve our financial goals.
The DSA margin was 27, 6% in the second quarter at 230 basis point increase from the second quarter of 2022.
Increase continued to be driven by operating leverage associated with higher revenue in our safety assessment business. In addition, we are closely monitoring capacity utilization for both physical infrastructure and labor, including the pace of capital spending and hiring and are committed to keeping these metrics closely aligned.
With the current demand environment is the DSA growth rate normalizes.
<unk> revenue was $209 $9 million, an increase of 13, 9% on an organic basis over the second quarter of 2022.
The RMS segment continued to benefit from broad based growth in all geographic regions for small research models and another exceptional performance from our insourcing solutions business.
Led by our Cradle initiative.
In addition, as we referenced last quarter, the timing of large module shipments within China benefited the second quarter growth rate, leading to the outperformance compared to our full year RMS outlook of high single digit organic growth the growth rate for small models in China also benefited from the comparison to last year's model.
Syntax COVID-19 related restrictions in the Beijing and Shanghai regions.
While growth rates cooled a bit in the second quarter, we are continuing to see stable demand and pricing for small research models in North America, and Europe , which reinforces our growth outlook for the year as.
As you know these models are essential tools that enables scientists to move their biomedical research programs forward. The stable demand trends also reflects a large base of wealth and the clients in the RMS segment is more than half of <unk> revenue is generated from academic and government institutions and large biopharma.
Most of our clients.
Services businesses continued to be the primary growth driver for Rms.
With insourcing solutions or is leading the way.
As cradle operations, continuing to expand and generate excellent client interest.
We recently opened a new site in Seattle in our first location Philadelphia, including these locations. We now have 32 cradles sites totaling over 400000 square feet in five states with growing bio hubs as well as in London in China.
The Philadelphia site is expected to cater to our large base of cell and gene therapy companies in the region.
Am I accurate, which we continue to believe we'll generate at finding growth opportunities across our portfolio.
Cradle network supports a flexible growth.
The entire life sciences ecosystem in each vial, allowing researchers to utilize our flexible vivarium rental space instead of building their own infrastructure.
In the second quarter, the RMS operating margin increased by 150 basis points to 26, 4%. This improvement was driven primarily by leverage from higher revenue growth in China.
Two the timing of large vital shipments and last year's Covid related impact.
The timing of large model shipments in China is not linear.
We are expecting in the third quarter RMS revenue growth rate and operating margin will be a bit lighter than the second quarter as a result of fewer shipments.
Revenue for the manufacturing solutions segment was $186 5 million, an increase of six 6% on an organic basis compared to the second quarter of last year.
Kris was driven by the CMO and microbial solutions businesses.
Actually offset by continued softer demand for biologics testing.
Our cell and gene therapy, <unk> business had a strong quarter reporting a solid double digit growth rate.
We are very pleased.
<unk> initiatives the CMO team implemented over the past 18 months to improve performance had been successful.
Beginning to generate the intended results.
<unk> of centers of excellence in gene modified cell therapy.
<unk> vectors and plasmids has more optimally aligned the business and investments in the commercial readiness of our operations and efforts to continue to improve the sales funnel for new projects have also contributed to the performance improvement.
We're also pleased to be working with our commercial cell therapy client in Memphis and have a few other clients who are nearing commercial launches.
Over the next one to two years at both Memphis, and our gene therapy Center of excellence in Maryland.
<unk> solutions delivered a solid second quarter performance led by the continued strength of the Acura <unk> microbial identification platform.
Last month, we were very pleased to have completed the launch of our <unk> safe Trillium.
Covenant Cascade reagent or our CR for bacterial endotoxin testing.
Let's see animal free solution reinforces our commitment to sustain an ability initiatives and provide sort of commented on alternative for them to save clients, who wish to become early adopters of more sustainable testing.
Methods Trillium utilizes three biological proteins, which we believe provides superior accuracy and testing outcomes to competitive single protein alternatives as well, it's equivalent to L. A L days testing measures.
With the launch of reagent kits in July we plan to have Trillium packages available this winter, which clients will be able to utilize in their existing <unk> systems for a seamless transition from la to al to.
Two our CR.
We believe the client that the option will be gradual over the next several years as most clients will likely continue to rely on our elas based and to save cartridges, which utilizes 95% less layout than traditional methods. The introduction of the animal free trillion solution.
<unk> supports our advancement of responsible science and further enhances our industry leading position as the only provider who can offer a comprehensive solution.
For rapid manufacturing quality control testing.
Testing volume in the biologics testing business improved from the seasonally soft first quarter level.
But the year over year growth rate continued to be pressured, particularly for viral clearance and cell banking services. We believe that performance is indicative of the current market dynamics of clients re prioritizing projects and becoming more budget focus, particularly for services that can be conducted at various times during the day.
And process the manufacturing segment's operating margin declined by 570 basis points year over year to 22, 9% in the second quarter of 2023, but did improve sequentially as anticipated.
Year over year decline was primarily driven by the biologics testing and <unk> businesses, but we do expect segment margin to continue to trend higher, particularly as the CMO performance continues to improve.
We were very pleased with our second quarter results, which gave us the confidence to narrow our 2023 revenue growth and non-GAAP earnings per share guidance to the upper ends of the previous ranges.
Although some demand trends are moderating we believe that the fundamental drivers of our business are intact, and we are well positioned to manage through any near term fluctuations for several reasons first.
<unk> are under intense pressure to bring new drugs to market. We believe they will always seek a large experienced scientific partner like Charles River, who can provide the greatest value to them through unmatched scientific expertise and flexible and efficient outsourcing solutions second.
Scale and duration of our DSA backlog provides us this ability to more effectively manage the business through timing and location using a global network of facilities and third we will continue to drive a culture of continuous improvement in speed and efficiency as a result of our digital transformation.
<unk>, which provides us with better access.
Two data and insights internally to appropriately manage costs and investments and enables our clients to access real time data E Commerce solutions and other self service tools and finally, we believe the power of our unique portfolio differentiates us today more than ever from other companies.
The R&D support services to the vial.
Souter coal industry.
As part of our annual strategic planning process. We recently completed a thorough review of the current market environment, our growth prospects and the strategic imperatives for our company through this process. We believe the current AD market trends could be characterized as a normalization from the past several years.
When there was unprecedented focus on and investment in biomedical research and scientific innovation. However, we are optimistic that we will be able to capitalize on the many opportunities that markets provide we intend to share more of our conclusions and update our longer term financial targets.
And our virtual Investor day, which we have planned for Thursday September 21.
To conclude I would like to thank our employees for their exceptional work and commitment and our clients and shareholders for their continued support now Flavia will provide additional details on our <unk>.
Second quarter financial performance and 2023 guidance.
Thank you Jim and good morning, before I begin may I remind you that I'll be speaking primarily to non-GAAP results, which exclude amortization and other acquisition related adjustment.
Costs related primarily to our global efficiency initiatives gains or losses from our venture capital and other strategic investments and certain other items.
Many of my comments will also refer to organic revenue growth, which excludes the impact of acquisitions divestitures and foreign currency translation.
We're pleased with our results for the second quarter, which included organic revenue growth of 11, 2% and non-GAAP earnings per share of $2 69.
These results, which are consistent with our prior outlook reflect the continued resilience and stability of our businesses.
Even during times of macroeconomic pressure.
As was the case in the first quarter increased interest expense, a higher tax rate and the divestiture of the avian vaccine business continued to restrict the year over year earnings growth rate.
Our first half results and our updated and HD supply outlook.
Our revenue growth and earnings per share guidance for the full year, which has now been narrowed to the upper end of the prior ranges.
We continue to be well positioned to deliver our reported revenue growth of two five to four 5% organic revenue growth of five five to seven 5%.
non-GAAP earnings per share between $10 30.
And $10 90.
And free cash flow of $330 million to $380 million for the year.
Our updated revenue growth outlook for 2023 reflects our revised assumptions about two headwinds that will affect the second half growth rates, particularly in the DSA segment.
First the impact of NH be supply is expected to be below our original estimate of 2% to 4% impact to total revenue growth.
This favorability will be largely offset by the impact of macroeconomic and funding pressures on biopharma client demand trends.
For the DSA segment, we expect the cumulative effect of these factors to result in a slightly more favorable outlook for the year with revenue growth rates in the mid single digits.
I will now reported and organic basis for the year.
The manufacturing segment benefited from continued traction in the <unk> business in the second quarter, but we expect continued pressure on the biologics Dustin growth rate due to a more budget focus client base.
As a result, we're reducing our reported growth outlook for the manufacturing segment to a low to mid single digit decline.
And narrowing our organic segment growth outlook to a high single digit increase.
The RMS segment growth outlook remains unchanged with a high single digit growth on both a reported and organic basis.
With regard to the consolidated operating margin for the full year, we expect the margin to be flat to slightly lower than in 2022.
We will continue our efforts to manage costs reduce discretionary spending and drive efficiency as well as monitor the demand environment to ensure our cost structure is closely aligned.
I will now provide some additional details on the non operating items in the second quarter.
Unallocated corporate costs totaled $65 1 million or six 1% of total revenue in the second quarter.
Compared to four 1% of revenue last year.
The increase was primarily related to the timing of corporate expenses, which fluctuate on a quarterly basis.
With a lower level in the first quarter corporate costs averaged five 2% of revenue in the first half of the year and we expect approximately 5% for the full year.
The second quarter tax rate was 23, 3%, representing a 220 basis point increase from the same period last year, but consistent with our full year outlook.
Year over year increase was primarily due to a lower benefit associated with stock based compensation and other headwinds related to discrete tax items for.
For the full year, we continue to expect the tax rate will be in the range of $22 five to 23, 5%, which is unchanged from the outlook we provided in may.
In the second quarter total adjusted net interest expense was $33 $6 million, which is essentially flat sequentially.
For the full year, we now expect total adjusted net interest expense will be in a range of $131 million to $134 million.
This is slightly lower than our prior outlook.
Merely as a result of our assumption.
Federal Reserve will take a less aggressive stance towards interest rate hikes for the remainder of the year.
As a reminder, at the end of the second quarter, approximately three quarters of about 268 billion.
That was at a fixed interest rate.
With regard to the variable rate portion of our debt our outlook can accommodate an additional 50 basis points of rate increases for the remainder of 2023.
At the end of the second quarter, our outstanding debt balance represented a gross leverage ratio of two one times and our net leverage ratio of two times, we continuously evaluate our capital priorities and intend to deploy capital to the areas that we believe will generate the greatest.
<unk>.
Over the longer term, we continue to believe that strategic acquisitions will generate the greatest shareholder return.
Hansen our growth potential.
The near term, we intend to continue to focus on battery statements.
Free cash flow was $87 million in the second quarter compared to $66 $6 million last year.
The year over year increase was primarily due to favorable changes in working capital.
For the year, our free cash flow guidance of $330 million to $380 million remains unchanged.
Capital expenditures with 67 $4 million in the second quarter compared to $82 9 million last year.
Primarily as a result of timing of projects.
We will continue to monitor monitor the demand environment and intend to keep capacity and capital investments closely aligned with market trends.
We continue to expect to make capital investments in the range of $340 million to $360 million for the full year, which is in the 8% range as a percent of total revenue.
A summary of our updated financial guidance for the full year can be found on slide 40.
We are expecting the second half consolidated organic revenue growth rate to average in the range of flat to low single digit growth.
The slower growth from first half levels.
Three principle factors <unk>.
Including the modest and HB related supply impact in the third quarter.
A more cautious biopharma spending environment.
It also difficult growth comparisons to the second half of last year.
These items will have the most significant impact on the DSA growth rates.
The manufacturing segment's performance is expected to continue to improve from the first half levels and the RMS segment is expected to continue to deliver solid performance with a third quarter Rms growth rate and operating margin a bit lighter due to the timing of large model shipments in.
<unk> lineup.
For the third quarter, we expect low single digit revenue growth on both a reported and organic basis.
non-GAAP earnings per share is expected to decline by approximately 10% from the third quarter 2022 level.
In closing we continue to focus on the execution of our strategy and delivering solid financial and operational results. We are pleased with our first half performance and despite some macroeconomic and funding pressures on our Biopharma clients. We believe the fundamental drivers of our business and now.
Solid financial position will enable us to successfully navigate this environment.
We operate in a durable industry with attractive long term growth prospects and will continue to leverage our capabilities expertise and proven strategy to fully support our clients' evolving needs and achieve our full year financial outlook.
You.
Okay.
That concludes our comments, we will now take your questions.
At this time, if you would like to ask a question. Please press the star and one on your telephone keypad.
You may remove yourself from the queue at any time by pressing star two.
Please limit yourself to one question and one follow up question once again that is star one.
To ask a question we.
We will pause for a moment to allow questions to queue.
And we will take our first question from Sandy Draper with Guggenheim. Your line is open.
Great. Thanks very much.
I apologize hopefully Jim you didn't cover this.
I had to jump on the call a little bit late but in terms of the.
Demand environment.
Is there a noticeable split between the types of customers large pharma midsized pharma and <unk>.
<unk> biotech.
Is it coming in any particular area.
By size by therapeutic class just any way to think about sort of or is it broad based that you're seeing sort of some a little bit more cautious is across all the different therapeutic classes and all the different sizes.
Pretty broad based for different reasons, obviously, the big pharma companies, which are.
Typically flushed with cash.
We have budget and they are.
Holding very tight so we've got it.
So careful.
Careful spending there.
And you've got a whole cadre of very small biotech companies with.
Some potential concern about burn rates and running out of cash.
We would say that essentially.
Both both of those groups have be careful subject to the following caveat that.
We had particularly.
Strong performance from pharmaceutical.
Alright.
In the second quarter. So its pharma companies are quite strong our growth rate has been used for the last decade, principally by small and midsize biotech big pharma has always been important.
Client base for us, but they have been particularly active and strong to a point.
And the point being budget so I'd.
I'd say some careful spending across the board would be probably the best way to characterize it.
Great. Thanks, Kevin I'll, just keep it to one question for now thanks.
Thanks Sandy.
Thank you and we'll take our next question from Eric Coldwell with Baird. Your line is open.
Thanks very much good morning, two part question on DSA first I know it's.
Modest and better than you originally expected but.
Would you care to quantify the.
More specifically quantify the third quarter impact from in Hps, and what Youre seeing for the full year versus the original 2% to 4%.
And then secondarily on the commentary around backlog declines in cancels, while that was I think fully anticipated I am curious what your.
Perspective is on the $2 8 billion today, how much of that do you think could be at risk or.
Maybe another way of saying is would you be looking at.
Similar backlog declines over the next 123 quarters, just trying to get a sense on what you think the underlying.
Safe basis in that that backlog that youre disclosing now thanks, so much.
Okay.
Difficult to say, where it settles out so we had.
Particularly frothy market and clients definitely.
Concerned about getting slots.
And so they booked they booked way out so we got as far outage 17, 18 months, we've talked about that.
We've got about 13 months of coverage right now, which feels good we will have less slippage slippage increase.
Sorry, we've always had slippage should increase just because of the sheer volume of work has increased by the same token.
I think people were holding slots without necessarily knowing what drug.
Wood.
But at the end of that slide that's exacerbated by the fact that everybody sort of refining their pipelines.
And so.
As things continue to normalize which they are and we think they will continue to I think the good news is that.
There'll be bookings studies somewhat closer to when they start so that's a good thing for them.
And for US, we should see a reduction in slippage for sure, but we should still have a substantial amount of business that backlog, where where it shakes out is a little bit difficult to call.
What we've said is normalizing and sort of returning to the mean and I think all of that is true.
We've gotten a significant amount to price.
Each year for the past half a decade anyway increasingly so because the studies are more complex.
To the current and the future we think that price will continue to see.
An important part of the equation as well.
Substantial volumes, so we'll just have to.
Walk through this together as we walk through the quarters, the other thing, which we keep saying that not sure.
We will pay a lot of attention to it. So we don't have the linearity of that business. So.
Last year, we had a very slow first half in a very strong second half.
This year, we had we've had a very strong first half and a less sort of pointing to a strong second half that doesn't necessarily tell you much.
Because our clients look at the spending throughout the whole year end.
I think we've been able to call so the annual cadence really well.
But we feel that that.
Business is good demand is solid comp, where we have a strong competitive.
Situation and that our clients will be.
Focusing on.
That is tied more rapidly than they have over the last two years.
Okay.
Yes.
First question about the.
Yesterday at the time.
We're not going to quantify it.
Lastly, I am just going to say that was meaningfully below the previous 2% to 4% range that we provided.
We are going to see a little bit of that in Q3, just as we operationalized.
Redistributing work across our.
Geographic fluctuated.
So it should be a small modest impact in Q3 and nothing in Q4.
One additional comment.
Hey, guys.
Lord.
In addition to everything that has been just that I think we pointed out that gross bookings.
We're above one.
The book to Bill in the quarter. So I think it's related to Jim's point gasoline work that was.
Place when that market was very frothy.
<unk>.
As you pointed out.
And if.
If gross bookings were above one.
As I think about this 12% revenue growth in this segment does that mean gross bookings were up 12% plus as well am I thinking about that right.
Uh huh.
There is other things, they're just price that is different year over year.
Necessarily job right conclusion, but gross bookings.
Supporting continued healthy growth with ESI.
Got it.
Okay. Thank you.
And we will take our next question from Derik de Bruin with Bank of America. Your line is open.
Hi, Good morning, Thank you for taking my question.
So I've got to Jim.
We continue to get a lot of questions from investors about thinking about how an HP pricing is going to roll through the businesses.
That normalizes and.
Pricing starts to come down and people are worried about your margins can you sort of walk through the <unk>.
Impact of what that has done in terms of <unk> price on your margins and just sort of how youre sort of thinking about mitigating that.
And that's kind of fallen.
I mean, the HP pricing has been primarily a pass through and so.
We've.
Where we're covering our cost and getting reimbursed.
Pat.
And so if and as those come down, which I think everybody expects that they will so it's a little bit.
To call it because.
The.
The ability of NIH piece sort of ebbs and flows, but let's assume that the sufficiency of that Matt.
We don't have the need to pass on anything incremental I mean, those those in Hp's studies have priced.
Appropriately given the complexity of the work given me.
Amount of labor.
Space, that's utilized given how prominent we are space. So I think we will continue to be able to hold on to very attractive prices there.
Without being significantly adversely impacted by not having that.
Somewhat unreasonable increased 70, if you look at the prices and Hp's over the last five or six years.
<unk> increased.
Not predictable right. So I think everybody would be pleased with that I think it will have a de minimis impact on us.
Great and as a follow up on the manufacturing segment.
High single digit growth now versus high single to low double digit prior just a little bit more color there in terms of.
Some of the headwinds in terms of the testing business and just what youre seeing with CDMA. We just basically the questions or goes into this it's like when do we expect that business to go back to.
Potential double digit growth rate is that is received is that feasible going back and looking at 2024.
So without getting specific about 'twenty four I would say, it's certainly feasible.
The microbial business, which is sort of tracking maybe.
High single has always been that low double so it has that potential given that.
Pricing in the complexity.
Diversity of the product lines. So that continues to be a very strong franchise for us since extremely profitable the CMO business, which.
It was a big headwind last year is improving nicely both on the top and the bottom line, so that should contribute well biologics business. So it's a little bit curious it always starts slow for that.
Not a big surprise.
Ste.
Reasonably slow again in the second quarter, but we anticipate it will continue to improve in the back.
Half of the year.
That testing has to be done in Detroit drugs.
A big push now is to get things into the clinic, what we're seeing that in some of this stuff is really expensive.
And viral clearance itself banking, which are which are expensive.
And I don't know a year or two ago, they might have done that earlier in the process of waiting until.
Later in the process. So as the drugs continued to develop well they will spend that kind of money we still.
Feel very good about that franchise and the investments that we've made in capacity and staffing.
That we've put in place for cell and gene therapy.
I think all of the problem.
From a competitive point of view, but the volume is such a bit of a drag right now.
So that will continue to ameliorate in the back half of the year.
Yes.
We are beginning to plan carefully for our Investor conference at the end of September .
Well, we'll try to give as much clarity.
We think the ebbs and flows around the specific businesses across the whole portfolio when we get there.
Thank you.
And we'll take our next question from Joseph <unk> with Morgan Stanley . Your line is open.
Hey, guys. Good morning, I wanted to go back to that earlier question on price, Jim If I may.
In the past you've always told us that clients are less focused on price and safety assessment more focused on start times.
Now, obviously that concern around stock times, no longer seems to be as acute anymore, and we will likely keep coming.
Coming in lower if you will so with that sort of backdrop and the macro crosscurrents that youre seeing how should we be thinking about pricing into sort of not just the back half of this year, but perhaps into 2024.
You should assume that pricing that we will continue to be able to garner meaningful price.
Given the complexity of the World you should assume.
Can't really speak for all of our competitors, but I will you should assume that capacity is going to be tight so.
While we can start studies faster.
The backlog is shorter the backlog is not trivial.
We're very busy on a worldwide basis, and we've added more capacity last year and this year, but only enough to accommodate for what we should be anticipated demand will be so I think as long as there's lots of healthy drug development, which is as long as there are multiple new modalities.
There are as long as.
Access to capital is improves which I think probably everybody on this call has a different sense, but the second quarter was better.
And yet there is more M&A and so if we have IPO marks athletic beginning of next year cash will be.
We are available so we are not.
Not a major focus.
Yes.
And of course if.
Got it that's also going to ebb and flow depending on how busy we are and depending on how people feel about the economy. So some of this is a sector related response.
A lot of it's just an overall economic.
Spot pricing will continue to be meaningful in terms of our ability to.
To get a significant amount.
The only caveat on that.
Hello.
Yes over obviously the last couple of years inflation had been unused.
Unusually high.
As Jim pointed out.
The complexity on the work that we perform we are able to pass.
Inflationary pressures to our clients and as that modulates the normalizes.
One of our class we will also adjust.
So that's the only thing to keep in mind.
Got it that's helpful.
And then Jim a quick follow up there.
Talks about sort of framing the long term targets at the analyst day.
But you also sort of mentioned that normalization of elevated growth that <unk> seen here over the past decade or so.
That sort of essentially sort of foreshadowing, perhaps your long term growth targets coming in a little bit to that high single digit range.
Yes, so you'll have to be patient.
<unk>.
We will give you chapter and verse.
Where we think we're going both topline and bottomline.
Let's wait until we do that math.
Alright. Thank you I appreciate it this time.
Thank you.
Take our next question from Dan Leonard with Credit Suisse. Your line is open.
Thank you.
My first question on the <unk> situation.
Sounds from your remarks that the <unk>.
<unk> solution you have in place to utilize your global footprint is permanent.
What are the implications of that for margins or otherwise.
So.
Nothing is forever.
Oh.
But it's possible that it is permanent right.
We're not looking at it as necessarily transitory look we're looking at it as.
Utilizing our infrastructure, which is bigger than everybody else's of clients and competitiveness.
Continuing to use it to our competitive advantage and that means multiple supply sources of NH fees.
Means multiple geographies and multiple facilities.
So the good news is we have a very big infrastructure, an enormous amount of expertise in.
In hps around the world and we will be able to see.
Slide and different providers have been hps, let's say in the U S market, if you don't bring them in Cambodia.
And if we do that we bring them in from Cambodia, then will use multiple sources. So.
I don't believe it's going to have any impact on our margin.
Without being too specific about what we're doing we're doing all this work, we're getting healthy price hits everywhere, obviously costs.
<unk> everywhere that we do work, but on a blended basis.
As we keep the volume up.
Should be able to generate hopefully increasingly better margins. We're also spending a lot of time and efficiency initiatives.
Digitization effort and sort of standardization of activities. So if a client.
We used to getting work done somewhere in the U S and now is getting it done for instance, somewhere in Europe .
Should feel the work will be identical.
Understood and I have a follow up Jim on your <unk> business.
You mentioned that you have a few other clients reaching commercialization in the next one to two years.
Possibly you could speak to whether any of these are more meaningful indications and could be more needle moving thank you.
Alright meaningful indications of why you cut out at the end.
Yes, more meaningful indications or more needle moving.
Okay.
Yes.
Very very difficult I mean that needle moving from the point of view that we're having.
Vigorous regulatory and client audits.
And.
Yes.
So both on both sides I think that puts us in a very rare position.
Competitive point of view, so we would anticipate that.
It gives us sort of.
Okay clean Bill of health at other clients will follow.
So both to gauge what the volume will be with these companies.
It's possible to gauge what the volume will ultimately be but I think most of these will start relatively slowly but from a regulatory point of view.
Insurance coverage point of view.
Doctors being comfortable with puts us I think you all know of cell and gene therapies five it's still lumpy whatever 14 drugs that have been approved so so it's a very serious safety profile.
<unk>.
We're thrilled to have multiple clients that are either commercial or talk seriously about it on.
Going through these audits.
Hopefully that will pick up and of course, almost regardless of the volume itself.
Youre doing the same thing over and over again, so so since the client is now in our commercial melia.
They should get more price, we should get more price as well and we should be able to continually refine.
And in the process. So there's only positive about.
The work putting that new commercial domain.
I appreciate those thoughts thank you.
Thank you we'll take our next question from Elizabeth Anderson with Evercore ISI. Your line is open.
Hey, guys. Thanks, so much further question.
Maybe I'm just sort of a two part question one on the short term side and one on the longer term side. If we talk about sort of what your commentary on DSA bookings and cancellations I'd be curious if you could talk about whether you saw the accelerating cancellations and continuing into July and then on the longer term.
End of the spectrum like can you help remind us like if we've gone through other sort of biotech funding cycles like if we think back to 2016 17 or even back to the financial crisis like how do we sort of.
Like thread sort of <unk>.
Proving biotech funding environment that we've been seeing a sort of cancellation commentary in terms of like when those things sort of the.
Funding sort of might come through to offset that thanks.
Yes, so we're going to stay away from giving intra quarter.
So we'll stay away from the July question, sorry about that.
The historical cycles are difficult to compare to because every single one of them is.
Something different is instigating at overall economic conditions are different and the client base is different both in terms of modality and scale.
And funding ability so it's tough to say.
<unk>.
And I've said for years I don't think this business is particularly cyclical.
But we're seeing a little of it now for sure with clients favoring the clinic.
Certainly to the detriment of some of the early discovery work I don't think much to the detriment of the.
Of the safety work, because you're not getting into the clinic.
Without that so again.
We feel that it's normalizing.
Brexit for RIS, we don't know exactly where it's going to shape out.
Yes.
Yep.
It was unusual it was fine, but it was unusually frothy.
And sort of instigated by Covid and real concerned about.
Running out of space. So I think we'll be in a.
It is a different place and I hope a better place where that the clients can book somewhat sooner.
Not necessarily overnight, but so much.
Prices hold up.
For sure cancellations would be reduced as a percentage.
The hole and we would be working much more closely with the client and having less kind of surprised is way down.
Good.
With the slippage so.
Yes.
Everybody is sort of saying the same thing the really big guys, saying look we have budgets and we cant Hello, guys are saying about where things are looking up but we need to be a little more cautious until things improve.
Depending on how you feel about the next year or two.
Most people think we will see an improved economy that should strengthen the demand and.
It should shake out in a more favorable place.
Got it that's helpful. And then just a quick follow up.
So the more global and HP work that you talked about before are you seeing an interest from non Chinese client in doing any work in China or is that kind of remain more dominated by Chinese.
Biopharma companies.
It's tough for us to say since we don't do work there so it's a bit anecdotal.
Some clients that are extremely price sensitive.
Tim.
Western clients will go to China.
Pondering said the work that is done in China is for us.
Chinese Crows for Chinese biotech or pharma companies, where it's essentially required by law.
So we see a little bit of that in conversations with prospective clients, but not very much.
Got it thanks, so much.
Thank you we'll take our next question from Dave Windley with Jefferies. Your line is open.
Hi, I wanted to clarify quickly in your answer to Eric Flavio did you say gross bookings about one times or above one times just interested in.
Or are we talking one one or one one or one point to just order of magnitude if you don't mind.
Good morning, Dave.
As I said above one.
That said precision.
We have online.
Okay.
Jim on the on the international or global activity and repositioning.
<unk> can you talk about.
You mentioned I think.
Conversations with regulators or work with regulators can you can you talk about the work that you've done there to get.
Either Canada or Europe European organizations comfortable.
With the supply chain in a way that the fish and wildlife service is not comfortable.
I, probably can't go too deep into that but.
We have other geographies that for sure from both regulatory at.
All remaining point of view.
Case in point of view support point of view are quite comfortable with the way we're operating.
A multiplicity of sources.
So it's just.
Just a different different approach.
We certainly hope that.
We get back to a similar relationship with the U S.
Obviously, we have that with non Cambodian animals.
And we think in time to continue conversations.
That will get to the point that.
We will have multiple sources of supply from multiple locations. So what are the sort of an interesting inflection point right now where we're getting lots of good news is we're getting our work done for our clients without delays.
We're doing a quality basis, we use kind of an infrastructure well.
Using a flexible way.
Have you gone about price.
And we're using the animals that we have contracted for.
We're happy and somewhat proud of.
Maybe to pivot.
In the midst of sort of a complex.
Situation, but.
I do think over time, it will continue to ameliorate.
And improve on a worldwide basis, that's certainly on the call.
Thank you and just as a quick follow up you mentioned the changes.
Just that I think youre still seeing price.
In the current just thinking short term in the current environment.
Given the changes in demand trend are you seeing discounting.
In the market from your competitors at all for safety assessment studies. Thanks, That's all I have.
Uh huh.
Yeah.
Depends on our competitor it depends on what sort of work we're bidding on I think that periodically there so.
More aggressive pricing certainly as I said earlier, there is from Chinese competitors.
These is from swapped some of our smaller competitors, sometimes we play we participate and sometimes the price points that they have set up are at or below our cost standpoint.
Trying to.
We're trying to trying to maximize the return we have a lot of long term contracts with some of our bigger clients, which has some price protection in it.
And probably periodically reducing prices as well so we'll do what we can to be responsive to different types of clients.
Many of whom have been concerned about it.
<unk> capital.
Mark as well the more complex work.
Last competition.
A little bit more.
Lastly.
Got it thank you very much.
Thank you we'll take our next question from Max Smock with William Blair. Your line is open.
Yeah.
Hi, Good morning, Thanks for taking my questions. Maybe just one for me here on the RMS segment thinking about demand for research models and indicator of health and stability of early stage research activity more broadly this quarter. We've consistently heard that companies are prioritizing later stage programs.
Send some more of the same today I'm just wondering how that isn't consistent with what youre seeing in RMS is there anything to call out there other than maybe your exposure to large well funded clients and how do you think about the likelihood that the macro environment starts to more meaningfully impact that segment moving forward. Thank you.
Yes.
The IMS business is particularly strong tomorrow.
Second quarter.
In large measure because of.
<unk> sales in China.
Service.
Significant service revenue, particularly.
Great I'll add small animals in the U S.
In Europe so.
While there may be less animals.
<unk> for discovery those animals are obviously used widely in pharmacology regulated and nonregulated talks.
So.
I think it will be de Minimis.
And youre not going to get drugs.
<unk>.
Next year or the year after.
Five years from now.
The discovery work guys.
Startup.
And African way again, so these.
Of.
Emphasis one place or another has to be short lived.
The development pipeline. So we continue to sell our research models literally everybody in the world.
The business.
Quite strong right now, we we always have and will it do get price.
And we have a much broader portfolio and geographic footprint than the competition. So.
Well it might be a little bit slow on the discovery side, if we hope.
It will continue to improve.
Got it. Thank you maybe just a follow up one for me here on manufacturing you mentioned weakness in things like viral clearance that don't need to necessarily be done right now but need to be done at some point I mean based on this and your visibility into the work that has kind of been delayed here is it fair to say that this work is actually simply being delayed instead of Kansas or then.
So how do you think about that work flowing through in the future or is there. Some bullish maybe building out that at some point, maybe 2024 could be a tailwind to the biologic safety testing business in particular.
That would be nice.
Not sure that that's happening, but it's very complex expensive.
It's a necessity drugs drugs don't get into the clinic unless you can.
Prove it to clear any sort of human viruses that IP in the mix.
We've seen it historically done earlier in the process.
And so.
Is it just simply it's a little bit.
Comparable to two.
Safety studies specialized safety studies in a way more expensive than clients wait until they're in phase II or III before they spend the money on that so it's not that unusual it's a very smart thing to do and you don't want to.
Expand the money on a drug that's not going to get to the clinic, which could have you do it prematurely.
It's difficult to extrapolate as to whether there's any sort of ball if at all so I wouldn't I wouldn't want to take a guess at that.
Thanks, Ed for short people.
So whittling down their pipelines it doesn't mean that theory.
Necessarily selling or canceling programs.
So that can heat up again and that could cause a bolus of work.
Across multiple work streams.
Okay.
Great. Thank you.
Thank you.
Take our next question from Patrick Donnelly with Citi. Your line is open.
Hey, guys. Thanks for taking the questions.
Jim maybe just circle back up on the backlog cancellation question I'll try to ask it a different way I mean, it looks like maybe $200 million or so of cancellations, maybe that's 7% of the backlog can you frame that up in terms of historically, what that looks like I'm just trying to get a sense of again a few people have asked what this looks like relative to <unk>.
Other cycles, how much is accelerated.
And just the right way to think about this going forward.
It's a right or wrong why you cut.
You've got you've got more work in backlog, which necessitate that necessitates, which brings with it more slippage and cancellation. So it's.
To some extent, it's math, but as it's elongated I think it's exacerbated it.
And increased itself.
It's not particularly comparable to other things that we've seen historically, which.
Which is fine.
That's sort of demand curve and competitive scenario.
Flexibly Mortalities continues to morph and change.
Over time.
But we definitely normalizing situation, which I think will be.
This situation and we still have <unk>.
13 months of backlog I think it'll be.
A better paradigm to predict for the next quarter and to come up with our operating plan for 2024, while.
While we do that.
Okay, That's fair and maybe just a quick one when we look at <unk> in terms of how it should be a relatively clean quarter in terms of note and HP headwinds is it fair to look at and it might be for Flavio as well on the EPS side is it fair to look at kind of DSA and EPS is a decent kind of run rate jumping off point.
When we look at 'twenty four is there anything left in terms of these headwinds are one time things that we need to consider on those pieces. Thank you guys.
Yes.
We will provide.
Additional.
Clarity 2024 now longer term.
The outlook in our Investor day on September 21.
But I think just in terms of <unk>.
Any impact of HD supply.
Said, there shouldnt be anything in Q4.
<unk> 2024.
Okay.
Alright.
Yes, I appreciate it.
And I think any one quarter as Jim said before that our business isn't linear so any one quarter's number a good indicator of a longer term trend necessarily I mean, we really take a lot of filing guidance on an annual basis and I think.
We've been pretty successful so.
So far.
Yes understood. Thank you guys.
Thank you and we will take our next question from Casey Woodring with Jpmorgan. Your line is open.
Great. Thanks for squeezing me in.
So you called out emerging biotech budgets as a key driver of some of the cancellations.
But you also mentioned that funding level showed the first year on year increase in seven quarters on a TTM basis last quarter. I think you gave a stat that industry funding grew 20% year over year. So curious on sort of the correlation there.
Maybe what your visibility is into emerging biotech demand DSA has always been a short cycle business. So.
Yes.
Cancellation rate is that more of a function of customers just choosing to book work, thus far in advance or is there a structural demand.
As you go along.
Thank you.
And the discovery.
Our work in discovery content very rapidly and comes out very rapidly.
The demand curve can turn on a dime as our client.
Smaller some midsized clients get more comfortable with their access to capital.
There's lots of tea leaves to read it right, it's follow ons and Ipos as money coming in from Big pharma, and BCS cetera, which.
He has to be strengthening.
At what point that clients are comfortable enough to prosecute a larger cadre of drugs.
Somewhat unclear, but seem to be moving.
In the right direction so.
We felt for a long time was five basis with extremely well financed.
And I wouldn't say that poorly financed right now I'd just say that.
There has been mounting concern about.
The weather access to capital will continue or not so.
Given that the tea leaves look positive we would think that at some point.
There would be more comfortable with that.
Right now there is definitely a enhanced focus clinic.
That makes a lot of sense, it's not a huge surprise.
But they have to get back to basic discovery sooner than later.
Got it and then maybe if I could just follow up quickly one for Flavia on the quarterly pacing in the back half for DSA.
The supply impact in the first half is mid teens that rolls off with no impact from supply in <unk>. As you noted based on the mid single digit guide for the year is that implied <unk> DSA growth rate flat to negative.
For <unk> and then maybe just talk about if that's the right way to think about it what that exit rate would mean for 24. Thank you guys.
Yes so.
Thank you.
Jim and I will address this in the prepared remarks, there is a few items impacting the second half any particular yesterday is a little bit.
The supply impact in the third quarter.
Just as the.
Finalized.
So we're.
Saturation of the market across our international.
Great.
There is also a key.
Paul If you will.
Last year.
Yesterday was incredibly strong in the second half.
Those comps impacting it there.
So I think as you look at.
As we guided to mid single digit and that for us.
Half of DSA.
17%, you will see a second half.
The deceleration of that growth rate.
If we can take the next question.
Thank you.
We'll move to our next question from Justin Bowers with Deutsche Bank. Your line is open.
Hey, good morning, everyone. Jim can you talk about the improvements and the CMO business and how Thats performing this year relative to the growth expectations when when.
<unk> entered the business couple of years ago.
Sure.
We've got three centers of excellence in that business now, which is a change from the companies that we bought so one company doing.
Gene modified cell therapy manufacturing, another windowing viral vector manufacturing.
<unk>.
Spoken previously we have enhanced changed.
Up upgraded.
Pretty much staffing across the board from sales for a regulatory sort of general managers.
We definitely have improving books of business in all three of those locales subjectivity caveat. They all have a slightly different.
The timeframe to generate new business as we said a moment ago. We do have a few clients that we're talking to about moving into a commercial domain.
Cell therapy manufacturing business so.
It takes some time for the world.
Actually acknowledging now that we're in.
In this business that we do it seriously what our products and services are.
How they can contrast that with others would take to do that.
Work with so we had a rough year last year for sure just kind of retooling.
These businesses that they feel like they're much stronger play.
Place right now clients seem much happier with regulators in.
No.
And so where we are.
Thanks for that that we're going to have higher growth rates this year and meaningful improvement over the past year over last year.
We anticipate that that will continue we have great hopes for these businesses. Both in terms of top line growth significant top line growth that would be accretive to both manufacturing for sure in the company as a whole and that the margins would improve as the scale of approved which we still believe.
Got it and then just in terms of the <unk>.
Normalization in DSA and we all appreciate.
Dynamic.
The last few years have been is there a way to.
Just sort of pair.
The commentary.
Before clients were booking.
More than you're out in advance.
Can you just help frame sort of what it was like.
Let's say, maybe pre pre COVID-19 and pre some of the supply chain disruption.
Why do we think it's sort of returns to that are somewhere in the middle.
Yes, Ken again.
A bit tough to say, but we probably had.
Six to nine month backlogs, depending on the type of tax specialty.
General and depending on the client and the locale.
They got much longer than that historically.
Never got more of that I'd say nine months. So the kind of pre COVID-19 was as it was in a good place.
And we have more price slightly than we used to in those days I hope would be that we get back to a recently.
Attractive run rate both allows us to take share and continue to cut our price should continue to be paid for the complexity of work.
And utilize our capacity.
Pretty comfortable with the capacity situation, both staff and space.
For us in the industry and for US, particularly since we're the largest player I think that plays very well to this.
Continuing to be in a financially beneficial business with hopefully improving operating margins over time.
Got it I appreciate it.
Thank you we'll take our next question from John <unk> with UBS. Your line is open.
Yeah.
Thanks for taking my question here.
Maybe just one.
Going into a little bit more on the microbial business within manufacturing. It sounds like this continues to be strong growth here you did this growth double digits in the quarter and maybe you could talk a little bit about the sustainability of the outlook here and where do you think this has the petro committed growth over the long term. Thanks.
So we're not going to break down the growth rate.
<unk> pieces.
We basins, but.
That business continues to have terrific technology.
IP that is quite advanced.
A broader portfolio of in any of the competitors using classic.
Capabilities that our cartridges and our conference rooms sooner comment version of that cartridge using less and less.
Crude out of the horseshoe crabs so.
Continued more automation in the utilization of Digitization, so that business, which is extremely profitable.
And we do think has the propensity.
More profitable.
And certainly.
Historical.
So and also has it sort of increasing connectivity with our biologics business.
Cell and gene therapy. So it was a little more of it.
It's always been an attractive business, but a little more of an outlier years ago and it feels much more central to the portfolio that it has historically.
We remain very positive about the current and future prospects of that business.
Okay.
Okay.
Please.
Thank you we'll take our next question from Jacob Johnson with Stephens. Your line is open.
Hey, Thanks, Good morning, maybe just one for me Jim on Cradle.
That seems to be a business, that's doing pretty well in this environment.
Can you just remind us kind of a mix of kind of small biotechs and pharma for that business and then I'm also curious if youre seeing cross selling opportunities from new client wins is that opening up new doors for Charles River.
Yes, the client base has been and continues to be very surprising.
So we thought it would be all tiny biotech companies that.
We're watching that cash and didn't want to commit to large amounts of space in places like Kendall square in Cambridge or South San Francisco.
And we have a bunch of those we have a surprising number of really.
Mid sized companies in big pharma companies, which is a surprise.
Because even a either run out of space, who don't want to build new space.
Have the hot new drug that they wanted to work on and so we love that so we had some very big.
Pharma footprint in many of these geographic locales.
So it's a business that is even more attractive than we originally thought and thats very high growth rates very high margins.
You'd be very impressed with the client.
Client base at each site similar sites get forward before we open the people go through the M&A kind.
Kind of commit to them.
As we've said previously I think the huge opportunity here is.
Because the preponderance of the work we do now is often supplying the animals and taken care of them while people do basic research and that's a perfectly good business by the way I think over time, we'll supply the animals take care of them and.
Participate with the client in running this study or do the entire study for that.
And yes, and whether or not we do that this is definitely a business that is currently and will continue to feed the <unk>.
So of our portfolio, particularly discovery and eventually safety, it's a drag looks promising so high.
High growth high margin business, if you looked at it on a see through basis, it's even higher growth and higher margin. I also think I don't mean to be a wise guy with his comment that it's relatively recession proof, it's probably the amongst recession proofing that we do because.
Yes, it's companies large and small totally depending on our.
Proximity and infrastructure to do the basic research. So we love. This business you saw in the prepared remarks, we have a lot of sites now.
A significant amount of square footage the acquisition that we did last year is doing extremely well, it's a smart thing for us to do and we'd love the geographic footprint.
I think we can have our last question. Please.
Hello Shelby.
And we'll take our last question from Tim Daly with Wells Fargo. Your line is open. Please ask your question.
Great. Thanks, just wanted to touch on RMS China here, so called out increased competition, specifically on the large mall side, that's consistent with news we've heard the countries. So just wanted to revisit the previously communicated expectations for RMS China to grow double digits in 'twenty three.
Can you update us on the current outlook for the year and any additional color would be great. If you could quantify RMS split between large and more margin.
Large and small models.
Is it for me thank you.
So.
Carl Sy.
Yes.
Large models.
<unk>.
I think every quarter that.
Numbers of animals is a little bit difficult to predict the price points.
Definitely it was beneficial to the RMS topline growth rate and margin for the quarter.
It continues to be a very attractive market for us it was adversely impacted a little bit over the last couple of years with Avi.
Covid Lockdowns.
We have several new facilities.
Trying to cover the whole country.
Competition continues to be local we're getting decent price.
We like both the growth rates at the margin. We're also beginning to see.
Significant improvement in the service businesses in China as we are seeing in the U S.
Europe so.
It's a marketplace as we've said many times, it's reminiscent of the U S and Europe , or maybe 20 or 25 years ago. So we would anticipate.
Additional continued high growth.
To be surprised by.
The lack of sort of.
The global players.
Still not getting into China. So we're.
Sort of on our own as the non Chinese entity.
Alright I appreciate it thank you for your time.
Thank you Larry.
We have no further questions in the queue I will turn the conference back over to Todd Spencer for closing remarks.
Thank you for joining us on our conference call. This morning, we look forward to seeing you at some upcoming investor conferences as well as our virtual Investor Day on September 21. This concludes the conference call. Thanks again.
Thank you that does conclude today's Charles River Laboratories second quarter 2023 earnings call. Thank you for your participation and you may now disconnect.
[music].
Mhm.
[music].
Hum.
[music].
Uh huh.
Uh-huh.
Uh huh.
[music].
[music].
[music].